Brevan Howard Capital Management LP Denali Therapeutics Inc. Transaction History
Brevan Howard Capital Management LP
- $14.2 Billion
- Q3 2024
A detailed history of Brevan Howard Capital Management LP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 11,161 shares of DNLI stock, worth $279,583. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,161
Previous 29,357
61.98%
Holding current value
$279,583
Previous $681,000
52.28%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding DNLI
# of Institutions
228Shares Held
120MCall Options Held
60.6KPut Options Held
48.4K-
Baillie Gifford & CO13.3MShares$334 Million0.3% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$330 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$280 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$269 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$198 Million0.05% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.36B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...